Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03150875
Recruitment Status : Active, not recruiting
First Posted : May 12, 2017
Results First Posted : June 23, 2021
Last Update Posted : June 23, 2021
Sponsor:
Information provided by (Responsible Party):
Innovent Biologics (Suzhou) Co. Ltd.

Brief Summary:

Similar clinical trial results demonstrated that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group. Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.

Additionally the correlation between PD-L1 expression and the response to IBI308 treatment in Chinese squamous cell NSCLC as well as the role of irRECIST in immune checkpoint inhibitor treatment evaluation will also be assessed


Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: IBI308 Drug: Docetaxel Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 290 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3)
Actual Study Start Date : September 1, 2017
Actual Primary Completion Date : July 31, 2020
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: IBI308
injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
Drug: IBI308
Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.

Active Comparator: docetaxel
injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
Drug: Docetaxel
As 2nd line treatment to subjects with squamous NSCLC




Primary Outcome Measures :
  1. Overall Survival [ Time Frame: Through database cutoff date of 31-July-2020 (up to approximately 35 months) ]
    Overall survival was defined as the time from randomization to death due to any cause.


Secondary Outcome Measures :
  1. Progression-free Survival by Investigators' Assessment [ Time Frame: Through database cutoff date of 31-July-2020 (up to approximately 35 months) ]
    Progression-free survival (PFS) was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumours (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions, or unequivocal progression of non-target lesion. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by investigators per RECIST 1.1 was reported for each arm.

  2. Overall Response Rate (ORR) Per RECIST v1.1 as Assessed by Investigators [ Time Frame: Through database cutoff date of 31-July-2020 (up to approximately 35 months) ]
    ORR was defined as the percentage of participants in the analysis population who had a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented.

  3. Duration of Response (DOR) Per RECIST v1.1 as Assessed by Investigators [ Time Frame: Through database cutoff date of 31-July-2020 (up to approximately 35 months) ]
    For participants who demonstrated a CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions or unequivoval progression of non-target lesion. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. The DOR per RECIST 1.1 for all participants who experienced a CR or PR is presented.

  4. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE) [ Time Frame: Through database cutoff date of 31-July-2020 (up to approximately 35 months) ]
    TEAE is any AE that developed or worsened in severity compared to the baseline during the period from first dose of any study treatment up to 90 days after the last dose of any study treatment. Percentage of participants experiencing TEAE is calculated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects with Histologically or cytologically confirmed squamous cell NSCLC
  2. Subjects with stage IIIB/stage IV or recurrent disease (not suitable for definitive concurrent chemoradiotherapy) (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) after failure of first-line platinum-based therapy; Subjects who developed recurrent disease <6 months after platinum-containing adjuvant, neoadjuvant or definitive chemoradiation therapy also could also be eligible.
  3. At lease one measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
  4. Age ≥ 18 and ≤ 75
  5. ECOG performance status 0-1
  6. Life expectancy of at least 12 weeks
  7. Adequate organ and bone marrow function

    1. CBC: absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; platelet count (PLT) ≥ 100 × 109 / L; hemoglobin content (HGB) ≥ 9.0 g / dL.
    2. Liver function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; serum albumin ≥ 28 g / L.
    3. Renal function: serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate (Ccr) ≥ 40 mL / min (calculated using Cockcroft / Gault equation) Female:CrCl= (140-Age) x Weight(kg) x 0.85 72 x Serum creatinine (mg/dL) Male:CrCl= (140-Age) x Weight(kg) x 1.00 72 x Serum creatinine (mg/dL)
  8. Subjects of reproductive potential must be willing to use adequate contraception during the course of the study and through 6 months after the last dose of study treatment.
  9. Voluntarily signed written informed consent form, willing and able to comply with scheduled visits and other requirements of the study

Exclusion Criteria:

  1. EGFR mutation and ALK rearrangement
  2. Mixed adeno-squamous carcinoma or other pathological type
  3. Prior therapy with anti-PD-1,anti-PD-L1,anti-CTLA4 antibody or docetaxel
  4. Have received following treatment:

    1. Received any investigational agent within 4 weeks of the first dose of study treatment.
    2. Received any anti-tumor therapy (chemotherapy, targeted therapy, tumor immunotherapy or arterial embolization) within 3 weeks of the first dose of study treatment.
    3. Received radiotherapy within 4 weeks of the first dose of study treatment.
    4. Received systemic treatment with high-dose corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive drugs within 4 weeks of first dose. Inhaled or topical steroids and adrenal replacement steroid are permitted in the absence of active autoimmune disease.
    5. Received attenuated live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period.
    6. Received major surgery (such as craniotomy, thoracotomy or laparotomy) within 4 weeks of the first dose of study drugs or open wound, ulcer or fracture.
  5. Unrecovered toxicity (grade >1, according to NCI CTCAE 4.03) due to prior anti-tumor therapy before the first dose of study treatment.
  6. Subjects with active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis, Crohn's disease, autoimmune thyroiditis. Subjects with cured childhood asthma, type I diabetes mellitus and hypothyroidism only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment.
  7. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation
  8. Known allergic or hypersensitive to docetaxel, any monoclonal antibody or any other components used in their preparation.
  9. Hemoptysis within 4 weeks of randomization (≥ 1/2 spoon per time).
  10. Received thoracic radiotherapy >30Gy within 6 months or palliative radiotherapy (brain or bone metastasis) ≤30Gy within 7 days of randomization.
  11. Symptomatic central nervous system (CNS) metastasis and/or carcinomatous meningitis. Subjects should have stable disease more than 4 weeks from first dose of study treatment, with neurological symptoms returned to NCI CTCAE 4.03 grade 0 or 1, are permitted to enroll.
  12. Subjects with a history of interstitial lung disease
  13. Superior vena caval obstruction syndrome;
  14. Uncontrolled third space effusion, eg. ascites or pleural effusion.
  15. Uncontrolled concomitant disease, including but not limited to :

    1. Active or poorly controlled severe infection
    2. Human Immunodeficiency Virus (HIV) infection (HIV antibody positive)
    3. Known acute or chronic active hepatitis B (HBV DNA positive) infection or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA positive) infection
    4. Active tuberculosis
    5. Symptomatic congestive heart failure (New York Heart Association grade III-IV) or symptomatic, poorly controlled arrhythmia
    6. Uncontrolled hypertension (SBP ≥ 160mmHg or DBP ≥ 100mmHg)
    7. Prior arterial thromboembolism event, including myocardial infarction, unstable angina, stroke and transient ischemic attack, within 6 months of enrollment
    8. Concomitant disease needs anticoagulant therapy
    9. Uncontrolled hypercalcemia(Ca2+>1.5mmol/L or Ca >12mg/dl or corrected Serum Calcium >ULN),or Symptomatic hypercalcemia during diphosphonate therapy
    10. Other primary malignancy, with the exception of: (radical Non-melanoma skin cancer or cured cervical in-situ carcinoma;)
  16. Subjects with other diseases or abnormal Lab test results which might increase the risk of enrollment and treatment or Interfere with the interpretation of study results could be excluded according to the judgments of investigator.
  17. Women who are pregnant or nursing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03150875


Locations
Layout table for location information
China, Zhejiang
The First Affiliated Hospital Zhejiang University
Hangzhou, Zhejiang, China
China
Jiangsu Cancer Hospital
Nanjing, China
Sponsors and Collaborators
Innovent Biologics (Suzhou) Co. Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Yuankai Shi, Doctor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
  Study Documents (Full-Text)

Documents provided by Innovent Biologics (Suzhou) Co. Ltd.:
Layout table for additonal information
Responsible Party: Innovent Biologics (Suzhou) Co. Ltd.
ClinicalTrials.gov Identifier: NCT03150875    
Other Study ID Numbers: CIBI308C301
First Posted: May 12, 2017    Key Record Dates
Results First Posted: June 23, 2021
Last Update Posted: June 23, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action